Register | Login
The Community Resource in Targeted Therapies
Driving Knowledge. Empowering Change. Optimizing Outcomes.
NEWS
CONFERENCES
VIDEOS
Case-Based Peer Perspectives
Expert Perspective Virtual Tumor Board
Interviews
Investigator Perspectives
Precision Medicine
PUBLICATIONS
Evolving Paradigms
Targeted Therapies in Oncology
The Journal of Targeted Therapies in Cancer
ONCAlert | Upfront Therapy for mRCC

Specialties >>

AML
Biosimilars
Bladder Cancer
Brain Cancer
Breast Cancer
CLL
Colorectal Cancer
DLBCL
EGFR+ Lung Cancer
Follicular Lymphoma
Gastric Cancer
Genitourinary Cancers
GI Cancers
Gynecologic Cancers
HCC
Head & Neck Cancers
Hematology
HER2-Negative Breast Cancer
Immunotherapy
Lung Cancer
Lymphomas
Mantle Cell Lymphoma
Melanoma
MPNs
Multiple Myeloma
Ovarian Cancer
Prostate Cancer
Renal Cell Carcinoma
Sarcoma
Skin Cancers
Thyroid Cancers

Partners >>

Dialogues in Diagnostics
Differential Diagnosis
Case-Based Peer Perspectives
Email Sign-Up

The Journal of Targeted Therapies in Cancer
2017 February

Clinical Articles

Missing Tumor-Specific Mutations Lead to Increased Resistance to Checkpoint Inhibitors
Axicabtagene Ciloleucel Demonstrates Safety and Efficacy in Lymphoma
Clinical Development of Cyclin-Dependent Kinase Inhibitors in Lung Cancer
Immune Checkpoint Inhibitors in CRC
Immune Checkpoint Approaches in AML and MDS: A Next Frontier?
Copyright © TargetedOnc 2018 Intellisphere, LLC. All Rights Reserved.